Neurologic Stem Cell Treatment Study
Launched by MD STEM CELLS · Jun 8, 2016
Trial Information
Current as of April 29, 2025
Recruiting
Keywords
ClinConnect Summary
The Neurologic Stem Cell Treatment Study is exploring a new way to help people with various neurologic disorders, such as Parkinson's disease, Alzheimer's, and traumatic brain injuries. The study involves taking stem cells from a patient's own bone marrow and injecting them into the bloodstream and nasal passages. Researchers want to see if this treatment can improve brain function in patients whose conditions haven't responded well to existing treatments.
To be eligible for this trial, participants should be at least 18 years old, have had their neurological condition for at least six months, and show signs of functional damage that isn't likely to improve with current treatments. They must also be medically stable and able to understand and agree to the study. If you decide to participate, you can expect to undergo a procedure to collect your stem cells and then receive treatment, along with regular follow-ups to monitor your health. It's important to note that women who can become pregnant must not be pregnant at the time of treatment and should avoid pregnancy for three months afterward.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.
- • 2. Be at least 6 months post-onset of the disease.
- • 3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.
- • 4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.
- • 5. Be over the age of 18 and capable of providing informed consent.
- • 6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.
- Exclusion Criteria:
- • 1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.
- • 2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.
- • 3. Patients must be capable of providing informed consent.
- • 4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .
- • 5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.
- • 6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.
About Md Stem Cells
MD Stem Cells is a leading clinical trial sponsor dedicated to advancing regenerative medicine through innovative stem cell therapies. Committed to rigorous scientific research and ethical practices, the organization focuses on developing groundbreaking treatments for various conditions, leveraging its expertise in cellular biology and patient-centered care. By collaborating with healthcare professionals and institutions, MD Stem Cells aims to translate cutting-edge research into effective clinical applications, ultimately improving patient outcomes and quality of life. Their commitment to safety, efficacy, and transparency underscores their role as a trusted partner in the evolving landscape of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Westport, Connecticut, United States
Coral Springs, Florida, United States
Dubai, , United Arab Emirates
Vienna, , Austria
Dubai, , United Arab Emirates
Patients applied
Trial Officials
Steven Levy, MD
Study Chair
MD Stem Cells
Jeffrey Weiss, MD
Principal Investigator
Coral Springs, Florida
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials